Clene (CLNN) AI Stock Analysis

• Market Cap: $37.80M
• Dividend Yield: N/A
• Average Volume (3M): 44.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: -41.36%
• EPS Growth: 41.82%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 8,325,843
• 10 Day Avg. Volume: 38,817
• 30 Day Avg. Volume: 44,002
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 86.05
• Price to Cash Flow (P/CF): -3.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $31.00
• Price Target Upside: 582.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Clene's overall stock score reflects significant financial difficulties and a challenging market position. Despite positive corporate events, such as FDA support and improved cash position, the company's persistent financial instability and bearish technical indicators weigh heavily on the score.

Positive Factors

Clinical Data

Clene shared new long-term survival data from cross-regimen post-hoc analyses comparing CNM-Au8 and zilucoplan, reinforcing CNM-Au8's survival benefits.

Regulatory Progress

The new observations support ongoing regulatory discussions with the FDA for potential accelerated approval of CNM-Au8.

Negative Factors

Regulatory Uncertainty

Earlier discussions with the FDA have not been very encouraging for Clene, which has been reflected in negative stock moves.

Clene Business Overview & Revenue Model

Company Description

Clene Inc. (CLNN) is a biopharmaceutical company focused on the development of novel therapeutics for neurodegenerative diseases. The company operates primarily within the biotechnology and pharmaceutical sectors, working to discover and develop innovative treatments targeting cellular energy production deficits. Its core products include investigational therapeutics designed to improve cellular function and address unmet medical needs in diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

How the Company Makes Money

Clene Inc. generates revenue primarily through the development and commercialization of its proprietary therapeutic candidates. The company seeks to advance its pipeline through clinical trials, aiming for regulatory approval and subsequent market entry. Revenue streams are anticipated from product sales once commercialization is achieved. Additionally, Clene may engage in strategic partnerships or licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties. These collaborations can significantly contribute to Clene’s financial performance by leveraging the partner’s distribution networks and expertise in specific markets.

Clene Financial Statement Overview

Summary

Clene's financial statements indicate significant financial challenges, including persistent losses, negative equity, and declining revenues. The company faces difficulties in achieving profitability and maintaining financial stability.

Income Statement

Clene's income statement reveals significant challenges, with negative gross profit and declining revenues over the periods. The company has a negative net profit margin, indicating substantial losses relative to revenue. Revenue decreased by 35.57% from 2023 to 2024, highlighting declining sales performance. The negative EBIT and EBITDA margins further underscore operational inefficiencies.

Balance Sheet

The balance sheet shows substantial financial instability, with negative stockholders' equity indicating insolvency. The debt-to-equity ratio is not applicable due to negative equity, but high total liabilities reveal significant leverage. The equity ratio is negative, further reflecting financial distress and a lack of asset backing by equity.

Cash Flow

The cash flow statement highlights negative operating and free cash flows, indicating the company is not generating sufficient cash from its operations. Despite a reduction in operating cash outflow from 2023 to 2024, the overall cash position remains precarious. The lack of positive cash flow raises concerns about the company's ability to sustain operations without external financing.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
421.00K	654.00K	473.00K	723.00K	206.00K	0.00
	Gross Profit
-511.00K	533.00K	447.00K	434.00K	141.00K	-900.00K
	EBIT
-34.37M	-40.54M	-45.33M	-45.28M	-17.00M	-16.33M
	EBITDA
-29.61M	-43.24M	-25.21M	-8.22M	-16.92M	-15.17M
	Net Income Common Stockholders
-36.02M	-49.50M	-15.28M	-9.74M	-19.28M	-16.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
35.00M	35.00M	23.32M	50.29M	59.27M	8.79M
	Total Assets
52.34M	52.34M	44.49M	63.06M	68.24M	14.88M
	Total Debt
32.16M	32.16M	31.82M	24.04M	4.32M	2.88M
	Net Debt
3.34M	3.34M	13.49M	-26.25M	-54.95M	-5.91M
	Total Liabilities
38.95M	38.95M	41.26M	50.47M	67.90M	82.65M
	Stockholders Equity
13.39M	13.39M	3.24M	12.60M	341.00K	-67.77M
Cash Flow		Free Cash Flow
-23.73M	-30.50M	-44.19M	-35.96M	-19.32M	-13.49M
	Operating Cash Flow
-23.68M	-30.17M	-39.01M	-34.62M	-18.93M	-13.20M
	Investing Cash Flow
100.27K	-1.50M	-10.16M	-1.33M	-387.00K	-294.00K
	Financing Cash Flow
-4.02M	42.16M	17.25M	27.11M	69.53M	5.50M

Clene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Negative. The current price of 4.54 is above the 20-day moving average (MA) of 4.48, below the 50-day MA of 4.72, and below the 200-day MA of 5.31, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 46.38 is Neutral, neither overbought nor oversold. The STOCH value of 59.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLNN.

Clene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
AVXL	48 Neutral	$763.88M	―	-37.72%	―	―	-3.08%
CYCN	45 Neutral	$6.95M	―	-30.36%	―	―	86.52%
CLNN	32 Underperform	$37.80M	―	-416.92%	―	-41.36%	41.82%
TRVN	31 Underperform	$1.28M	―	145.94%	―	-82.94%	33.10%

Clene Corporate Events

Clene Secures $10M Debt Facility to Enhance Position

Clene has secured a $10 million debt facility with affiliated entities Kensington, 4Life, and La Scala to repay its existing obligations to Avenue Capital and improve its financial position. This new debt facility, which carries a 12% interest rate and is partially convertible into common stock, enhances Clene’s cash position, enabling the company to gather additional data needed for the FDA’s accelerated approval process for its CNM-Au8 drug for ALS. This move reflects Clene’s ongoing commitment to advancing its therapeutic pipeline and maintaining strong relationships with its investors.

Clene Gains FDA Support for ALS Treatment Approval

Clene, a company involved in developing treatments for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has outlined a potential path for accelerated approval of its CNM-Au8 treatment in ALS through additional biomarker data submission. This development could significantly impact Clene’s operations by potentially speeding up the approval process, enhancing its market position in the neurodegenerative treatment industry, and providing a promising option for stakeholders invested in ALS treatments.

Clene Announces Q3 2024 Results and ALS Drug Progress

Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced its third quarter 2024 financial results, highlighting a meeting with the FDA to discuss accelerated approval for its ALS treatment CNM-Au8. The company raised $7.3 million through stock offerings and amended its debt agreement to extend its financial runway into early 2025. Despite a net loss of $8 million, Clene aims to continue its groundbreaking work in improving neuronal health.